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1. Introduction 
The studies of Jefferson et al. [l] and of Menahan 
and Wieland [Z] provided evidence for a regulatory 
role of 3’, 5’AMP in the antago~sm of glucagon and 
insulin on the isolated perfused liver. From the fact that 
insulin counteracted the effect of glucagon on gluconeo- 
genesis, urea production and ketogenesis, but failed to 
antagonize the stimulation of these parameters by Nz, 
O6 dibutyryl-adenosine 3’, 5’-phosphate, an interac- 
tion of these two hormones at a step at or prior to the 
formation of the cyclic nucleotide was proposed [2], In 
adipose tissue homogenates, Jungas observed an inhibi- 
tion of net Ado3’, S-P formation after previous treat- 
ment of the tissue with insulin [3] and from the work 
of Butcher et al. [4], and Hepp et al. [S] an effect of 
insulin on the adenyl cyclase system of isolated fat cells 
could be inferred. However, several groups who where 
studying adenyl cyclase in different preparations from 
adipose tissue, did not find a significant effect of in- 
sulin in uitro 16-91. On the other hand, a protein frac- 
tion prepared from mamm~ian serum and termed non- 
suppressible insulin-lee activity (NSILA) [ 10, 121 
was shown to i~bit the formation of 3’, S-AMP in 
adipocytes [9]. In the course of studies on glucagon 
action upon adenyl cyclase activity in mouse liver [ 111 
an antagonistic action of insulin and NSILA was ob- 
served. In the present communication these effects are 
described and a possible mechanism of action in the 
complex receptor-enzyme system is proposed. 
2. Materials and methods 
Particulate homogenate fractions were prepared from 
fresh livers of male Swiss albino mice (35-40 g) which 
North-Holland Publishing Company - Amsterdam 
were fed a normal laboratory chow ad lib. The method 
as well as the test for adenyl cyclase activity have been 
described in detail [ II]. Crystalline bovine insulin 
(27 U/mg, lot No. 211024) was obtained from Farb- 
werke Hoechst, crystalline porcine insulin (25 U/mg, 
lot No. S 13868, 10 times rec~st~lized) from the 
NOVO Company. D~utions were made in aqueous 
solutions of 3 mg/ml crystalline bovine albumin (Beh- 
ringwerke), resulting in a final concentration of 300’ 
pg/ml in the test. Control samples received albumin 
solutions alone. Synthetic glucagon was a gift of Dr. E. 
Wiinsch, Max-Planck-Institut fur Eiweiss- und Leder- 
forschung, Munich. NSILA-S [ 121 preparations I, II 
and III were from the laboratory of Dr. R. Froesch, 
Zurich. Their specific biological activity per mg dry 
weight was equivalent to 0.1, 1 and 10 mU of crystal- 
line insulin, respectively. Part of preparation I was in- 
activated by reduction and aminoethylation which 
resulted in the complete loss of its biological activity. 
Control samples contained an equal amount of pro- 
tein as crystalline albumin. All hormones were added 
to the test mixture before starting the reaction with 
the addition of the liver preparation. 
3. Results 
3.1. Effects of crystalline insulin 
Table 1 shows the effect of 100 pU/ml of crystal- 
line bovine insulin on adenyl cyclase activity which 
was submaximally [ 111 stimulated by synthetic glu- 
cagon (see also fig. 1). A 33% inhibition (of total ac- 
tivity) was observed which, on the basis of paired 
comparison, was highly significant. The effect could 
be reproduced with equal concentrations of porcine 
insulin. In the presence of calcium, which inhibits 
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Table 1 
Effect of crystalline insulin of glucagon stinulated adenyl cyclase activity in mouse liver in presence and absence of calcium. 
Assay system according to [ 111. ATP/Mg ratio 1:2. 
Additions No of 
expts. 
Adenyl cyclase activity A 
(nmoles X g protein- r X 
P 
min-’ f S.E.M.) 
None 6 6.3 f 1.5 + 22.6 + 5.7 
Glucagon (0.5 pg/ml) 6 28.9 k 6.1 
Glucagon (0.5 pg/ml) - 9.7 + 1.7 <O.OOl 
+ insulin (100 pU/ml) 6 19.2 f 6.2 
Ca2+ (1 mM) 5 3.1 f 1.1 
Ca2+ (1 mM) + glucagon 5 13.6 * 2.8 + 10.5 * 2.1 
(0.5 rg/ml) 
Ca2+ (1 mM) + glucagon - 7.7 f 2.1 <O.Ol 
(0.5 pg/ml) + insulin 5 5.9 f 1.5 
(100 fiU/ml) 
both the basal and the glucagon effect, the inhibition 
was relatively stronger (56%). Fig. 1 shows a dose re- 
sponse curve of glucagon in presence and absence of 
bovine insulin. Although an inhibition could be also 
observed when maximal doses of glucagon were pre- 
sent, the curves shown can not exclude a competitive 
mechanism. It should be noted that the present assay 
system contained concentrations of 32 P-ATP which 
were far below saturation, and that no methylxanthines 
were present [ 111. 
3.2. Effect of NSILA-S and RAE-NSZLA-S 
NSILA-S, [ 10, 121, inhibited glucagon-stimulated 
adenyl cyclase over a concentration range which cor- 
responds to its biological action (table 2). In contrast 
to its inhibition of the glucagon effect, no antagonism 
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Fig. 1. Dose response curve of synthetic glucagon in presence (0) and absence (0) of 100 MU/ml of crystalline insulin. Data from 
two experiments are given as percent stimulation above basal values. ATP/Mg ratio 1:2. 
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Table 2 
Effect of NSILA-S and biologically inactive RAE-NSILA-S on glucagon- or fluoride-stimulated adenyl cyclase activity in mouse 
liver. Biological activity is expressed as nU-equivalents, as standardized with crystalline insulin on rat adipose tissue in vitro [ 10, 121 
Test system for adenyl cyclase according to [ 111. ATP/Mg ratio was 1: 10. 
Additions jGequivalents/ml Adenyl cyclase activity 
(nmoles X ,g protein-l X 
mint) 
Experiment I 
Glucagon (5 &ml) 
+ albumin (200 &g/ml) - 42.0 
+ albumin (195 pg/ml) + NSILA-S 111(5 pg/ml) 50 38.3 
+ albumin ( 190 fig/ml) + NSILA-S Ill (10 wg/ml) 100 35.8 
+ albumin (150 pg/ml) + NSILA-S III (50 pg/ml) 500 26.8 
+ NSILA-S (200 Hg/ml) 2000 18.1 
Experiment II 
Albumin (500 pg/ml) - 3.9 
Albumin (500 rg/ml) + glucagon (5 pg/ml) - 54.6 
RAE-NSILA-S (500 ng/ml) + glucagon (5 pg/ml) 0 54.8 
NSILA-S I (500 pg/ml) + glucagon (5 pg/ml) 50 30.0 
Albumin (500 pg/ml) + NaF (10 mM) - 70.6 
NSILA-S II (500 ng/ml) + NaF (10 mM) 500 84.3 
to fluoride stimulation could be observed (table 2). 
Furthermore, when a different preparation (NSILA-S 
I) was inactivated by reduction and aminoethylatron, 
it had also lost its effect on the adenyl cyclase system. 
A non-specific effect of these still impure fractions 
seems thus unlikely. 
4. Discussion 
In a recent publication, Ray and coworkers have 
described an effect of very high concentrations of in- 
sulin on basal and glucagon-stimulated adenyl cyclase 
activity of isolated plasma membranes of rat liver [ 131. 
Since the properties of their adenyl cyclase preparation 
differ in several respects from those seen with the pres- 
ent mouse liver fraction [ 1 l] , entirely different en- 
zyme systems may have been under study. In the pres- 
ent communication, physiological concentrations of in- 
sulin were shown to be active. 
In view of the well known sensitivity of the mouse 
to insulin in vim it seemed advantageous to investigate 
the effect of this hormone on an adenyl cyclase pre- 
paration from mouse liver. Indeed, when similar rat 
liver preparations were studied in preliminary experi- 
ments, the effects were smaller and more variable. 
Other factors, such as the absence of the methyl- 
xanthines, the presence of albumin, and the use of 
submaximal concentrations of synthetic glucagon in 
the assay, may have been helpful. Of interest is the 
finding of a relative increase of the insulin effect in the 
presence of Ca’+. In view of the observation that in- 
sulin enhanced the binding of Ca2+ to artificial mem- 
branes [ 141 it seems attractive to speculate that the 
hormone may antagonize glucagon action in such a 
way. Since even highly purified insulin is not a homoa 
geneous substance, it is not absolutely certain that 
the insulin molecule itself has caused the effect. It 
should be noted, however, that several insulin prepa- 
rations of different origin were active in the physiolog- 
ical concentration range. Since NSILA shares many 
metabolic effects with crystalline insulin, it repre- 
sents an interesting model substance. Since prelimin- 
ary experiments showed that its interaction with glu- 
cagon was non-competitive, maximal glucagon con- 
centrations were used. The fact that NSILA inhibits 
the glucagon but not the fluoride stimulated cyclase 
system, represents an additional difference in the 
characteristics of glucagon and fluoride stimulation 
[ 111. It suggests that insulin activity may interact 
with glucagon directly at its receptor site or with the 
transmission of the hormone signal to the catalytic 
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(fluoride stimulated) unit of the adenyl cyclase sys- 
tem. 
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